VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5-mutated proteasome inhibitor resistant multiple myeloma

Abstract The introduction of proteasome inhibitors (PIs) into multiple myeloma (MM) treatment has substantially improved therapeutic options and survival rates. However, the development of resistance to PIs as well as serious side effects of PI treatment continue to justify the search for effective,...

Полное описание

Библиографические подробности

Главные авторы:	Ellen Leich-Zbat, Sofia Catalina Heredia-Guerrero, Marietheres Evers, Thorsten Stühmer, Tina Grieb, Hilka Rauert-Wunderlich, Ralf C. Bargou, Andreas Rosenwald, Manik Chatterjee, Daniela Brünnert
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Nature Portfolio 2026-03-01
Серии:	Scientific Reports
Предметы:	Multiple myeloma Proteasome inhibitors PYK2 VS-4718 Carfilzomib Proteasome inhibitor resistance
Online-ссылка:	https://doi.org/10.1038/s41598-026-43205-4
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!